Scholar Rock Holding (SRRK) Notes Payables (2021 - 2024)
Scholar Rock Holding's (SRRK) quarterly Notes Payables came in at $1.6 million in Q2 2024, down 71.13% quarter-over-quarter from $5.5 million in Q1 2024.
Scholar Rock Holding (SRRK) Notes Payables (2021 - 2024) Analysis & Trends
Scholar Rock Holding's Notes Payables history runs 4 years deep, the most recent figure standing at $1.6 million for Q2 2024.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $1.6 million in Q2 2024; TTM through Jun 2024 was $1.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.3 million, changed N/A from the prior year.
- Notes Payables fell to $1.6 million in Q2 2024 per SRRK's latest filing, from $5.5 million in the prior quarter.
- Across five years, Notes Payables topped out at $11.6 million in Q2 2022 and bottomed at $805000.0 in Q3 2022.
- The 4-year median for Notes Payables is $1.6 million (2024), against an average of $4.1 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Sep 30, 2022 | 805,000.00 |
| Jun 30, 2022 | 11.58 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 1.58 Mn |